Recent

% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

  • medxwatcher medxwatcher Sep 26, 2013 5:56 PM Flag

    INCB 039110 Looks like it could become a blockbuster

    Data from abstracts courtesy of BoAML. This is really exciting folks, and should propel the share price to new highs shortly.

    Table 1:Efficacy profile for JAK inhibitors and anti-TNFs in RA
    ACR20 ACR50 ACR70
    INCB-039110 day 84 (~12wks)
    100mg BID (n=8) 50% 38% 25%
    300mg QD (n=9) 44% 44% 22%
    200mg BID (n=8) 50% 38% 13%
    600mg QD (n=7) 100% 71% 57%
    Placebo (n=8) 38% 25% 13%
    Phase 2b baricitinib 24 weeks
    2mg baricitinib (n=52) 63% 20% 10%
    4mg baricitinib (n=50) 78% 48% 28%
    8mg baricitinib (n=50) 73% 55% 24%
    Phase 2b baricitinib 24 weeks 71% 41% 21%
    Phase 2b baricitinib 52 weeks extension 71% 49% 27%
    ORAL SYNC tofacitinib 24 weeks
    5mg tofacitinib (n=315) 53% 34% 16%
    10mg tofacitinib (n=318) 58% 37% 13%
    Placebo 31% 13% 3%
    ORAL STANDARD tofacitinib 24 weeks
    5mg tofacitinib (n=204) 52% 37% 20%
    10mg tofacitinib (n=201) 53% 35% 22%
    Placebo (n=108) 28% 12% 2%
    Phase 2a VX509 12 weeks
    25mg VX509 (n=41) 39% 17% 7%
    50mg VX509 (n=41) 61% 32% 12%
    100mg VX509 (n=40) 65% 38% 18%
    150mg VX509 (n=41) 66% 49% 22%
    Placebo (n=41) 29% 7% 2%
    Phase 2a GLPG0634 28 days
    '634 100mg 2x/day (n=12) 92% NA NA
    '634 200mg 1x/day (n=12) 75% NA NA
    Placebo (n=12) 33% NA NA
    Phase 2a GLPG0634 28 days
    '634 30mg 1x/day (n=17) 35% 12% NA
    '634 75mg 1x/day (n=22) 55% 28% NA
    '634 150mg 1x/day (n=15) 40% 1% NA
    '634 300mg 1x/day (n=20) 65% 45% NA
    Placebo (n=17) 41% 6% NA
    Biologics 24 weeks
    Humira (ABT) 46% 22% 12%
    Humira (ABT) 53% 35% 18%
    Enbrel (AMGN) 59% 40% 15%
    Simponi (JNJ/MRK) 60% 37% 20%
    Remicade (JNJ/MRK) 50% 28% 10%
    Cimzia (UCB) 59% 37% 21%

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
INCY
101.66-1.10(-1.07%)Apr 17 4:00 PMEDT